Work

Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2551

Authors: M Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, Russell Zelig Szmulewitz, Thomas Powles, Roberto Pili, Justine Yang Bruce, Ulka N. Vaishampayan, James M. G. Larkin, Brad Rosbrook, Mariajose Lechuga, Olga Valota, Jamal Christo Tarazi, Dale Randall Shepard

Institutions: Massachusetts General Hospital, University of Minnesota, Masonic Cancer Center, Huntsman Cancer Institute, University of Chicago, Barts Cancer Institute, Indiana University Indianapolis, University of Wisconsin–Madison, The Barbara Ann Karmanos Cancer Institute, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Pfizer (United States), Cleveland Clinic

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2689998510

Cites:

Cited by: 1

Related to: 10